<DOC>
	<DOCNO>NCT00072852</DOCNO>
	<brief_summary>The purpose phase II , randomize , open-label clinical trial study 2 schedule single-agent Irinotecan woman metastatic breast cancer experience failure prior therapy anthracycline , taxane , capecitabine . Patients receive Irinotecan capsule either day 5 day , day 14 day 3 week cycle .</brief_summary>
	<brief_title>Irinotecan Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure Anthracycline , Taxane , Capecitabine</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Women diagnosis primary adenocarcinoma breast Presence locally advance metastatic disease nonamenable surgery radiation therapy curative intent At least one measurable lesion &gt; 20mm ( &gt; 10 mm spiral CT scan ) Must receive ( fail ) prior treatment anthracycline , taxane , capecitabine adjuvant and/or advance disease treatment set Women least 18 year old , performance status 02 Prior treatment another topoisomerase I inhibitor Current enrollment another clinical trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
</DOC>